Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13693MR)

This product GTTS-WQ13693MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13693MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ867MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ3844MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ1643MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ5390MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ10052MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ4303MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ3051MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ15202MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW